CommercialCoverageMedium impact
06.02.29d, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)
Independence Blue Cross·Cardiology, Cardiothoracic Surgery, Transplant Surgery·Pharmacy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators reissued policy 06.02.29d regarding AlloMap™ Molecular Expression Testing for heart transplant rejection evaluation. This is a recent policy reissuance (1 month old) effective 03/05/2025. Billing teams must review the full policy text to identify any coverage, coding, authorization, or documentation changes from the previous version.
Action Required
By 03/05/2025: Billing team must obtain and review the complete policy text at the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-29d) to identify specific CPT/HCPCS codes, prior authorization requirements, coverage criteria, and documentation standards for AlloMap testing. Update billing system rules, encounter forms, and provider alerts accordingly. Communicate changes to cardiothoracic surgery and transplant teams. Claims submitted without compliance to updated policy requirements will be subject to denial.